Navigation & orchestrationRank #10 of 12Companion

Transcarent

Item: Transcarent
Rating: 7.1
Author: MyGLP Reviews

Care orchestration that routes members and enforces benefit policy

Founded 2020 · San Francisco, CA · Private · Website

7.1Adequate

Weighted score

Adequate

Reviewed September 19, 2026

PMPM benchmark

$12–$32

Category planning band — not a vendor quote. Excludes drug spend.

Our verdict

Strong infrastructure for multi-vendor environments at 5,000+ lives. Redundant if you have a single clinical partner. Negotiate the savings baseline methodology before anything else.

Scorecard

How it scored

Scored against the published rubric. Weights are fixed before review and identical for every vendor.

How scoring works

Clinical rigor6.4

Prescriber credentials, titration protocol, comorbidity screening, and off-ramp planning.

Outcomes evidence6.2

Quality of published results: peer review, sample size, control group, and follow-up duration.

Cost control8.4

Ability to hold net pharmacy spend down: gating, biosimilar strategy, and risk sharing.

Data & reporting8.1

Eligibility-level reporting, claims feeds, and whether you can audit the vendor's own numbers.

Integration8.8

PBM, carrier, HRIS, and point-solution interoperability without custom engineering.

Member experience7.3

Time to first appointment, app quality, care-team continuity, and support responsiveness.

Analysis

What we found

Transcarent is not competing with the clinical vendors here; it sits above them. For a large employer with several overlapping point solutions, the orchestration layer solves a real and expensive problem: eligibility rules that exist on paper but are enforced inconsistently in practice. The economics are attractive and savings guarantees are genuinely central rather than decorative. The caveat is scope — this is infrastructure, not care, and it adds a layer only worth paying for when there are multiple vendors to coordinate.

Strengths

Lowest PMPM in the evaluation and the only vendor that routinely puts savings guarantees at the center of the contract
Enforces your eligibility policy consistently across every downstream vendor, which is hard to do manually
Integration breadth rivals Teladoc without the burden of a full clinical stack

Limitations

Delivers no clinical care itself, so you still need to buy and manage a clinical vendor underneath it
Outcomes evidence is book-of-business white-paper material, not independently reviewed
Only justifies its overhead in genuinely multi-vendor environments

Best for

Large employers running several point solutions who need consistent policy enforcement and routing across all of them.

Watch out

Savings guarantees are measured against a baseline the vendor helps construct. Negotiate the baseline methodology first — it matters more than the guarantee.

The details

Commercial and clinical specifics

The facts you will need to build a comparison grid. Verify each against the vendor's own documentation before contracting.

Pricing

Model: PMPM across the full eligible population, often with risk-based components
PMPM range: $12–$32
Setup fee: Bundled
Medications included: No
Performance guarantees: Savings guarantees are central to the model

Contract

Minimum lives: 5,000
Term: 36 months
Termination notice: 120 days

Eligibility

BMI threshold: Fully employer-configurable
Prior authorization: Yes
Step therapy: Yes
Comorbidity required: No

Clinical model

Prescribes: No
Care team: Care guides, Nurses, Clinical review team
Titration protocol: Not applicable — routes to contracted clinical vendors
Off-ramp: Managed through the downstream clinical partner
Formulary: None directly — orchestrates access through partners

Outcomes evidence

Headline claim: Reduced inappropriate utilisation and improved routing to lower-cost sites of care, reported in company white papers
Evidence level: White paperVendor-authored, methodology disclosed but not independently reviewed.
Sample size: Employer-specific book of business
Follow-up: Varies by employer engagement

Sources

Transcarent insights and white papersCompany-authored analyses; methodology disclosed but not independently peer reviewed

Outcomes verified 2026-09-19. Pricing and contract figures on this page are category planning benchmarks, not vendor quotes — see methodology.

Integrations

PBMs: CVS Caremark, Express Scripts, Optum Rx, Prime Therapeutics
Carriers: Aetna, Cigna, UnitedHealthcare, BCBS plans
HRIS: Workday, ADP, UKG, Oracle, Paycom
Eligibility file: 834, daily cadence

Formulary

Transcarent by medication

How a vendor positions each molecule reveals more about its cost discipline than any single score. First-line means an eligible member can start immediately; escalation means a documented lower-cost trial comes first.

Transcarent Reviews Semaglutide

GLP-1 receptor agonist

Orchestrated

Transcarent neither prescribes nor dispenses. It triages members, routes them to a contracted clinical vendor, and enforces your semaglutide eligibility policy consistently across every downstream partner — which is difficult to do manually across a multi-vendor stack.

Read pairing

Transcarent Reviews Tirzepatide

Dual GIP/GLP-1 receptor agonist

Orchestrated

Same routing and policy-enforcement posture. The value is consistency: one rule set applied to tirzepatide across every downstream vendor, rather than five vendors interpreting your policy five ways.

Read pairing